Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker; J. Mark FitzGerald; Pascal Chanez; Alberto Papi; Steven F. Weinstein; Peter Barker; Stephanie Sproule; Geoffrey Gilmartin; Magnus Aurivillius; Viktoría Werkström; Mitchell Goldman

doi:10.1016/s0140-6736(16)31324-1

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

著者: Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F. Weinstein, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Magnus Aurivillius, Viktoría Werkström, Mitchell Goldman - The Lancet 2016 被引用: 1,380

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Litlas